---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-108447"
form_type: "8-K"
ticker: "VIVS"
cik: "0001497253"
company_name: "VivoSim Labs, INC."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:06:20.561822+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# VivoSim Labs appoints Tony Lialin as Chief Commercial Officer

## Summary
- Tony Lialin appointed CCO effective Aug 11, 2025; leads go-to-market strategy for NAMkind liver/intestine 3D models.
- Annual salary $360,000, sign-on bonus $10,000, target bonus up to 40% of base salary.
- Granted option to purchase 40,000 shares vesting over 4 years (25% cliff at 1 yr, then quarterly).
- Company cites global liver/GI in-vitro market at $641M in 2024, U.S. share 50.8% ($325M).

## SEC filing metadata
- accession: 0000950170-25-108447
- form_type: 8-K
- ticker: VIVS
- cik: 0001497253
- company_name: VivoSim Labs, INC.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1497253/000095017025108447/0000950170-25-108447-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1497253/000095017025108447/vivs-20250814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-108447
- JSON: https://secwatch.observer/filing/0000950170-25-108447.json
- Plain text: https://secwatch.observer/filing/0000950170-25-108447.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.